AbbVie (ABBV) Deferred Taxes (2019 - 2026)

AbbVie (ABBV) has reported Deferred Taxes for 8 consecutive years, with -$195.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Deferred Taxes rose 28.31% year-over-year to -$195.0 million in Q2 2026; TTM through Jun 2026 was -$250.0 million, a 81.4% increase from a year earlier, with the FY2025 full-year figure at -$492.0 million, up 66.05% from the prior year.
• Deferred Taxes was -$195.0 million for Q2 2026 at AbbVie, down from $137.0 million in the prior quarter.
• Over five years, Deferred Taxes peaked at $193.0 million in Q3 2025 and troughed at -$1.4 billion in Q4 2023.
• A 5-year average of -$378.8 million and a median of -$322.5 million in 2023 frame the typical range for Deferred Taxes.
• Across the five-year window, Deferred Taxes tumbled 1726.47% in 2022 and surged 589.29% in 2026, its largest moves.
• Over 5 years, Deferred Taxes stood at -$516.0 million in 2022, then sank by 169.57% to -$1.4 billion in 2023, then soared by 44.86% to -$767.0 million in 2024, then surged by 49.8% to -$385.0 million in 2025, then soared by 49.35% to -$195.0 million in 2026.
• The last three Deferred Taxes figures came in at -$195.0 million (Q2 2026), $137.0 million (Q1 2026), and -$385.0 million (Q4 2025), per Business Quant data.